References: Julius M, Lang CA, Gleiberman L, Harburg E, DiFranceisco W, Schork A
In the lean stack protocol , it functions as the metabolic regulator by: Activating GLP-1 receptors to suppress appetite and slow gastric emptying Activating GIP receptors to enhance insulin sensitivity in adipose tissue Activating glucagon receptors to increase energy expenditure and fat oxidation Reducing body weight through combined anorectic and thermogenic effects Improving glycaemic control in metabolic research models Retatrutide has demonstrated the most significant weight reduction of any incretin-based compound in Phase 2 clinical data, with mean reductions of 24.2% over 48 weeks at the highest dose making it the centrepiece of the lean stack protocol
Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain
Activation of Poly (ADP-ribose) polymerase (PARP) DNA repair depletion and worsened inflammation neuronal dysfunction
Miroz PA, Finan B, Gelfanov V et al (2019) Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
